Recent advances and future directions in the management of metastatic renal cell carcinoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2010, Pages 225-235

  Ansari, J ^a   Glaholm, J ^b   McMenemin, R ^c   James, N D ^b   Hussain, S A ^b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bevacizumab; Everolimus; Interferon; Metastatic renal cell carcinoma; Sorafenib; Sunitinib; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; IMATINIB; INTERFERON; PAZOPANIB; PERIFOSINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

CLINICAL TRIAL; DRUG POTENTIATION; ENDOTHELIUM CELL; GENE MUTATION; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; MEDICAL LITERATURE; METASTASIS; PATHOGENESIS; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 77950851926     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009030225     Document Type: Review

References (59)

1. Lindblad, P.; Adami, H.O. In Textbook of Cancer Epidemiology, Adami, H., Ed.; Oxford University Press: New York, 2002; pp. 467-485.
2. UK Kidney cancer incidence statisitics. Available at http://info. cancerresearchuk.org/cancerstats/types/kidney/incidence/#source10
3. Wirth, M.P. Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. North Am., 1993, 20(2), 283-295 (Pubitemid 23154478)
4. Fisher, R.I.; Rosenberg, S.A.; Fyfe, G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am., 2000, 6(1), S55-7.
5. Clifford, S.C.; Prowse, A.H.; Affara, N.A.; Buys, C.H.; Maher, E.R. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer, 1998, 22(3), 200-209
6. Cho, D,; Signoretti, S.; Regan, M.; Mier, J.W.; Atkins, M.B. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin. Cancer Res., 2007, 13(2), S758-763.
7. Land, S.C.; Tee, A.R. Hypoxia-inducible factor 1 alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem., 2007, 282(28), 20534-20543
8. Mendel, D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, .; Schreck, R.E.; Abrams, T.J.; Ngai, T.J.; Lee, L.B.; Murray, L.J.; Carver, J.; Chan, E.; Moss, K.G.; Haznedar, J.O.; Sukbuntherng, J.; Blake, R.A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res., 2003, 9, 327-337
9. Grandinetti, C.A.; Goldspiel, B.R. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy, 2007, 27(8), 1125-1144 (Pubitemid 47173659)
10. Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; Hudes, G.R.; Wilding, G.; Figlin, R.A.; Ginsberg, M.S.; Kim, S.T.; Baum, C.M.; DePrimo, S.E.; Li, J.Z.; Bello, C.L.; Theuer, C.P.; George, D.J.; Rini, B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24(1), 16-24. (Pubitemid 46630489)
11. Motzer, R.J.; Rini, B.I.; Bukowski, R.M.; Curti, B.D.; George, D.J.; Hudes, G.R.; Redman, B.G.; Margolin, K.A.; Merchan, J.R.; Wilding, G.; Ginsberg, M.S.; Bacik, J.; Kim, S.T.; Baum, C.M.; Michaelson, M.D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 2006, 295(21), 2516-2524 (Pubitemid 43854967)
12. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; Chen, I.; Bycott, P.W.; Baum, C.M.; Figlin, R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 2007, 356(2), 115-124
13. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Oudard, S.; Negrier, S.; Szczylik, C.; Pili, R.; Bjarnason, G.A.; Garcia-Del-Muro, X.; Sosman, J.A.; Solska, E.; Wilding, G.; Thompson, J.A.; Kim, S.T.; Chen, I.; Huang, X.; Figlin, R.A. Overall Survival And Updated Results For Sunitinib Com pared With Interferon Alfa In Patients With Metastatic Renal Cell Carcinoma. J. Clin. Oncol., 2009, 27(22), 3584-3590
14. National Institute for Health and Clinical Excellence: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. NICE Technology Appraisal Guidance 169, March 2009, (www.nice.org.uk/TA169).
15. Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; Rolland, F.; Demkow, T.; Hutson, T.E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R.M.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med, 2007, 356(2), 125-134 (Pubitemid 46089673)
16. Strumberg, D.; Clark, J.W.; Awada, A.; Moore, M.J.; Richly, H.; Hendlisz, A.; Hirte, H.W.; Eder, J.P.; Lenz, H.J.; Schwartz, B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist, 2007, 12(4), 426-437
17. Ratain, M.J.; Eisen, T.; Stadler, W.M.; Flaherty, K.T.; Kaye, S.B.; Rosner, G.L.; Gore, M.; Desai, A.A.; Patnaik, A.; Xiong, H.Q.; Rowinsky, E.; Abbruzzese, J.L.; Xia, C.; Simantov, R.; Schwartz, B.; O'Dwyer, P.J. Phase II placebo-controlled randomised discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24, 2505-2512. (Pubitemid 46630627)
18. Ljungberg, B.; Hanbury, D.C.; Kuczyk, M.A.; Merseburger, A.S.; Mulders, P.F.; Patard, J.J.; Sinescu, I.C. Guidelines on Renal Cell Carcinoma. 2009, Available at http://www.uroweb.org/ fileadmin/tx-eauguidelines/2009/Full/RCC.pdf
19. Yang, J.C.; Haworth, L.; Sherry, R.M.; Hwu, P.; Schwartzentruber, D.J.; Topalian, S.L.; Steinberg, S.M.; Chen, H.X.; Rosenberg, S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med., 2003, 349(5), 427-434
20. Skotnicki, J.S.; Leone, C.L.; Smith, A.L. Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin. Cancer Res., 2001, 7, 3749S-50S.
21. Atkins, M.B.; Hidalgo, M.; Stadler, W.M.; Logan, T.F.; Dutcher, J.P.; Hudes, G.R.; Park, Y.; Liou, S.H.; Marshall, B.; Boni, J.P.; Dukart, G.; Sherman, M.L. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol., 2004, 22(5), 909-918 (Pubitemid 41103603)
22. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I.G.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R.J. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med., 2007, 356(22), 2271-2281 (Pubitemid 46849157)
23. Amato, R.J.; Jac, J.; Giessinger, S.; Saxena, S.; Willis, J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer, 2009, 115(11), 2438-2446
24. Rixe, O.; Bukowski, R.M.; Michaelson, M.D.; Wilding, G.; Hudes, G.R.; Bolte, O.; Motzer, R.J.; Bycott, P.; Liau, K.F.; Freddo, J.; Trask, P.C.; Kim, S.; Rini, B.I. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol., 2007, 8(11), 975-984 (Pubitemid 47629888)
25. Sosman, J.A.; Puzanov, I.; Atkins, M.B. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin. Cancer Res., 2007, 13(2. Pt. 2), 764s-769s.
26. Shaheen, R.M.; Ahmad, S.A.; Liu, W.; Reinmuth, N.; Jung, Y.D.; Tseng, W.W.; Drazan, K.E.; Bucana, C.D.; Hicklin, D.J.; Ellis, L.M. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer, 2001, 85(4), 584-589 (Pubitemid 32808285)
27. Hainsworth, J.D.; Sosman, J.A.; Spigel, D.R.; Edwards, D.L.; Baughman, C.; Greco, A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol., 2005, 23(31), 7889-7896 (Pubitemid 46657387)
28. Bukowski, R.M.; Kabbinavar, F.F.; Figlin, R.A.; Flaherty, K.; Srinivas, S.; Vaishampayan, U.; Drabkin, H.A.; Dutcher, J.; Ryba, S.; Xia, Q.; Scappaticci, F.A.; McDermott, D. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol., 2007, 25(29), 4536-4541 (Pubitemid 350035309)
29. rd.; Farley, C.; Cucullu, H.; Yost, K.; Hart, L.L.; Sylvester, L.; Waterhouse, D.M.; Greco, F.A. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin. Genitourin Cancer, 2007, 5(7), 427-432
30. Zimmermann, K.; Schmittel, A.; Steiner, U.; Asemissen, A.M.; Knoedler, M.; Thiel, E.; Miller, K.; Keilholz, U. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology, 2009, 76(5), 350-354
31. Eichelberg, C.; Heuer, R.; Chun, F.K.; Hinrichs, K.; Zacharias, M.; Huland, H.; Heinzer, H. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol., 2008, 54(6), 1373-1378
32. Dudek, A.Z.; Zolnierek, J.; Dham, A.; Lindgren, B.R.; Szczylik, C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer, 2009, 115(1), 61-67
33. Tamaskar, I.; Garcia, J.A.; Elson, P.; Wood, L.; Mekhail, T.; Dreicer, R.; Rini, B.I.; Bukowski, R.M. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol., 2008, 179(1), 81-86
34. Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grünwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; Urbanowitz, G.; Berg, W.J.; Kay, A.; Lebwohl, D.; Ravaud, A.; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 2008, 372(9637), 449-456
35. von Marschall, Z.; Scholz, A.; Cramer, T.; Schäfer, G.; Schirner, M.; Oberg, K.; Wiedenmann, B.; Höcker, M.; Rosewicz, S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst., 2003, 95(6), 437-448 (Pubitemid 36432418)
36. Motzer, R.J.; Hudes, G.; Wilding, G.; Schwartz, L.H.; Hariharan, S.; Kempin, S.; Fayyad, R.; Figlin, R.A. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin. Genitourin Cancer, 2009, 7(1), 28-33.
37. Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; Gorbunova, V.; Bay, J.O.; Bodrogi, I.; Jagiello-Gruszfeld, A.; Moore, N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 2007, 370(9605), 2103-2111 (Pubitemid 350296300)
38. Rini, B.I.; Halabi, S.; Rosenberg, J.E.; Stadler, W.M.; Vaena, D.A.; Ou, S.S.; Archer, L.; Atkins, J.N.; Picus, J.; Czaykowski, P.; Dutcher, J.; Small, E.J. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol., 2008, 26(33), 5422-5428
39. Motzer, R.J.; Mazumdar, M.; Bacik, J.; Berg, W.; Amsterdam, A.; Ferrara, J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol., 1999, 17(8), 2530-2540 (Pubitemid 29368255)
40. Kirkwood, J.M.; Tarhini, A.A. Biomarkers of therapeutic response in Melanoma and Renal cell Carcinoma: Potential inroads to improved immunotherapy. J. Clin. Oncol., 2009, 27(16), 2583-2585
41. Parker, A.S.; Leibovich, B.C.; Lohse, C.M.; Sheinin, Y.; Kuntz, S.M.; Eckel-Passow, J.E.; Blute, M.L.; Kwon, E.D. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer, 2009, 115(10), 2092-2103
42. Rini, B.I.; Jaeger, E.; Weinberg, V.; Sein, N.; Chew, K.; Fong, K.; Simko, J.; Small, E.J.; Waldman, F.M. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int., 2006, 98(4), 756-762
43. Choueiri, T.K.; Vaziri, S.A.; Jaeger, E.; Elson, P.; Wood, L.; Bhalla, I.P.; Small, E.J.; Weinberg, V.; Sein, N.; Simko, J.; Golshayan, A.R.; Sercia, L.; Zhou, M.; Waldman, F.M.; Rini, B.I.; Bukowski, R.M.; Ganapathi, R. von Hippel-Lindau (VHL) gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal carcinoma. J. Urol., 2008, 180(3), 860-865
44. Golshayan, A.R.; Brick, A.J.; Choueiri, T.K. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Fut. Oncol., 2008, 4, 85-92.
45. Rini, B.I.; Michaelson, M.D.; Rosenberg, J.E.; Bukowski, R.M.; Sosman, J.A.; Stadler, W.M.; Hutson, T.E.; Margolin, K.; Harmon, C.S.; DePrimo, S.E.; Kim, S.T.; Chen, I.; George, D.J. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol., 2008, 26(22), 3743-3748
46. Sabatino, M.; Kim-Schulze, S.; Panelli, M.C.; Stroncek, D.; Wang, E.; Taback, B.; Kim, D.W.; Deraffele, G.; Pos, Z.; Marincola, F.M.; Kaufman, H.L. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J. Clin. Oncol., 2009, 27(16), 2645-2652
47. Sly, W.S.; Hu, P.Y. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu. Rev. Biochem. 1995, 64, 375-401
48. Loncaster, J.A.; Harris, A.L.; Davidson, S.E.; Logue, J.P.; Hunter, R.D.; Wycoff, C.C.; Pastorek, J.; Ratcliffe, P.J.; Stratford, I.J.; West, C.M. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res., 2001, 61(17), 6394-6399
49. Giatromanolaki, A.; Koukourakis, M.I.; Sivridis, E.; Pastorek, J.; Wykoff, C.C.; Gatter, K.C.; Harris, A.L. Expression of hypoxia inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res., 2001, 61(21): 7992-7998
50. Chia, S.K.; Wykoff, C.C.; Watson, P.H.; Han, C.; Leek, R.D.; Pastorek, J.; Gatter, K.C.; Ratcliffe, P.; Harris, A.L. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol., 2001, 19(16), 3660-3668
51. Bui, M.H.; Seligson, D.; Han, K.R.; Pantuck, A.J.; Dorey, F.J.; Huang, Y.; Horvath, S.; Leibovich, B.C.; Chopra, S.; Liao, S.Y.; Stanbridge, E.; Lerman, M.I.; Palotie, A.; Figlin, R.A.; Belldegrun, A.S. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res., 2003, 9(2), 802-811
52. Sandlund, J.; Oosterwijk, E.; Grankvist, K.; Oosterwijk-Wakka, J.; Ljungberg, B.; Rasmuson, T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int., 2007, 100(3), 556-560 (Pubitemid 47205465)
53. Leibovich, B.C.; Sheinin, Y.; Lohse, C.M.; Thompson, R.H.; Cheville, J.C.; Zavada, J.; Kwon, E.D. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J. Clin. Oncol., 2007, 25(30), 4757-4764 (Pubitemid 350086478)
54. Li, G.; Feng, G.; Gentil-Perret, A.; Genin, C.; Tostain, J. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J. Urol., 2008, 180(2), 510-513
55. Patard, J.J.; Fergelot, P.; Karakiewicz, P.I.; Klatte, T.; Trinh, Q.D.; Rioux-Leclercq, N.; Said, J.W.; Belldegrun, A.S.; Pantuck, A.J. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int. J. Cancer, 2008, 123(2), 395-400.
56. Bui, M.H.; Visapaa, H.; Seligson, D.; Kim, H.; Han, K.R.; Huang, Y.; Horvath, S.; Stanbridge, E.J.; Palotie, A.; Figlin, R.A.; Belldegrun, A.S. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J. Urol., 2004, 171(6. Pt. 1), 2461-2466
57. Vroling, L.; van der Veldt, A.A.; de Haas, R.R.; Haanen, J.B.; Schuurhuis, G.J.; Kuik, D.J.; van Cruijsen, H.; Verheul, H.M.; van den Eertwegh, A.J.; Hoekman, K.; Boven, E.; van Hinsbergh, V.W.; Broxterman, H.J. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis, 2009, 12(1), 69-79.
58. Klatte, T.; Seligson, D.B.; Leppert, J.T.; Riggs, S.B.; Yu, H.; Zomorodian, N.; Kabbinavar, F.F.; Strieter, R.M.; Belldegrun, A.S.; Pantuck, A.J. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J. Urol., 2008, 179(1), 61-66
59. Shvarts, O.; Seligson, D.; Lam, J.; Shi, T.; Horvath, S.; Figlin, R.; Belldegrun, A.; Pantuck, A.J. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J. Urol., 2005, 173(3), 725-8.]